 | Up a level |
Journal Article
Younes, Anas, Sehn, Laurie H., Johnson, Peter 
ORCID: 0000-0003-2306-4974, Zinzani, Pier Luigi, Hong, Xiaonan, Zhu, Jun, Patti, Caterina, Belada, David ORCID: 0000-0002-4981-6188, Samoilova, Olga, Suh, Cheolwon, Leppae, Sirpa, Rai, Shinya, Turgut, Mehmet, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Cheung, Matthew C., Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Duehrsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram, Carey, Jodi, Liu, Grace, Shreeve, S. Martin, Sun, Steven, Zhuang, Sen Hong, Vermeulen, Jessica, Staudt, Louis M., Wilson, Wyndham, Fisher, Richard I., Engert, Andreas, Stadtmauer, Edward A. and Wei, Lee-Jen
(2019).
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
J. Clin. Oncol., 37 (15).
S. 1285 - 1307.
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Belada, David ORCID: 0000-0002-4981-6188, Georgiev, Pencho ORCID: 0000-0001-5677-6754, Dakhil, Shaker, Inhorn, Lowell F., Andorsky, David, Beck, J. Thaddeus, Quick, Donald, Pettengell, Ruth, Daly, Robert, Dean, James P., Pavlyuk, Mariya, Failloux, Nelly and Huebel, Kai
(2016).
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Future Oncol., 12 (15).
S. 1759 - 1769.
LONDON:
FUTURE MEDICINE LTD.
ISSN 1744-8301